Solid evidence supporting the involvement of 5-HT in the pathophysiology of migraine is linked to the efficacy of 5-HT2 antagonists, such as methysergide and pizotifen, as prophylactic drugs and 5-HT1B/D agonists, such as triptans, for acute management. This evidence concerns the gene HTR5A and migraine disorder.